FDA, Orexigen Discussing CV Risk Study For Weight-Loss Drug Contrave
This article was originally published in The Pink Sheet Daily
Executive Summary
Timing of the study to be discussed at Dec. 7 advisory committee meeting.
You may also be interested in...
FDA Panel Backs Approval Of Takeda/Orexigen's Obesity Drug Contrave
The promise of a randomized clinical trial to examine the cardiovascular risks of Orexigen's weight-loss drug Contrave - inlicensed by Takeda for North American commercialization and development rights - prompted a 13-7 vote in favor of approval by the agency's Endocrinologic and Metabolic Drugs Advisory Committee Dec. 7
FDA Panel Backs Approval Of Orexigen's Obesity Drug Contrave
Promised post-market randomized clinical trial to assess cardiovascular risk tips the panel in favor of the naltrexone/bupropion combination.
FDA Panel Backs Approval Of Orexigen's Obesity Drug Contrave
Promised post-market randomized clinical trial to assess cardiovascular risk tips the panel in favor of the naltrexone/bupropion combination.